ArticleJournal of perinatology : official journal of the California Perinatal Association2025
Management of the patent ductus arteriosus among infants born at 23 to 32 weeks' gestation between 2011 to 2022: a report from in the Children's Hospitals Neonatal Consortium.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Variations in diagnosis and management of hemodynamically significant patent ductus arteriosus across neonatal intensive care units in the Children's Hospitals Neonatal Consortium.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Select plasma oxylipins as potential biomarkers of effective indomethacin treatment response in preterm infants with patent ductus arteriosus.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Optimal timing for transcatheter device occlusion of a hemodynamically significant patent ductus arteriosus in preterm infants: evidence, uncertainty, and future directions.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Frequency and outcomes of surgical and transcatheter closure of patent ductus arteriosus in preterm infants in Germany-a prospective nationwide hospital-based surveillance study.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study reports on patent ductus arteriosus (PDA) therapy trends across the Children's Hospital Neonatal Consortium. STUDY
designWe performed a 12-year (2011-2022) retrospective study of premature infants (< 33 weeks) with a PDA. We utilized descriptive statistics to compare demographic, inpatient, and discharge characteristics in 3-year epochs.
resultFrom 54,813 infants, 19,843 (36%) had a diagnosis of PDA. Use of pharmacotherapy increased 44% (relative) over time, mostly with increased acetaminophen use. There was a 12.7-fold increase in exposure to multiple PDA medications over the study period. While the rate of definitive closure did not change, use of transcatheter PDA closure increased from 0 to 20.3% and surgical ligation decreased from 25.1% to 3.6%.
conclusionThere has been an increase in the use of multiple pharmacotherapies for PDA, especially among infants born <27 weeks' gestation. Transcatheter PDA closure has overtaken surgical ligation as the primary method of definitive PDA closure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.